Evidence map›Paper›PMID 31819425›Full record

ArticleInternational journal of nanomedicine2019

cRGDfK-Grafted Small-Size Quercetin Micelles For Enhancing Therapy Efficacy Of Active Ingredient From The Chinese Medicinal Herb.

Pengcheng Xu, Haisheng Wang, Hongxiang Hu, Yong Ye, Yu Dong, Suxin Li, Dong Mei, Zhaoming Guo, Dan Wang, Yanxue Sun and 3 more

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Pengcheng XuDepartment of Pharmaceutical Engineering, College of Pharmacy, Inner Mongolia Medical University, Hohhot 010110, People's Republic of China.ORCID 0000-0002-1783-5755
Haisheng WangDepartment of Biochemistry, College of Basic Medical Sciences, Inner Mongolia Medical University, Hohhot 010110, People's Republic of China.
Hongxiang HuBeijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing 100191, People's Republic of China.
Yong YeDepartment of Pharmaceutics, College of Pharmacy, Guangxi Medical University, Nanning 530021, People's Republic of China.
Yu DongDepartment of Pharmaceutical Engineering, College of Pharmacy, Inner Mongolia Medical University, Hohhot 010110, People's Republic of China.
Suxin LiBeijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing 100191, People's Republic of China.
Dong MeiBeijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing 100191, People's Republic of China.ORCID 0000-0002-0801-8702
Zhaoming GuoBeijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing 100191, People's Republic of China.ORCID 0000-0003-1295-6838
Dan WangBeijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing 100191, People's Republic of China.
Yanxue SunDepartment of Pharmaceutical Engineering, College of Pharmacy, Inner Mongolia Medical University, Hohhot 010110, People's Republic of China.
Tengfei YuDepartment of Pharmaceutical Engineering, College of Pharmacy, Inner Mongolia Medical University, Hohhot 010110, People's Republic of China.
Junchan QiaoDepartment of Pharmaceutical Engineering, College of Pharmacy, Inner Mongolia Medical University, Hohhot 010110, People's Republic of China.
Qiang ZhangBeijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing 100191, People's Republic of China.
Inner Mongolia Medical University · CNPeking University · CNGuangxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAs an active ingredient of Chinese herbal medicine, quercetin (QU) can significantly induce apoptosis of tumor cells and give play to other effect such as decreasing both fibroblast population and collagen in cancer cell nest. However, the antitumor efficacy of quercetin was mostly evaluated at cellular level and rarely developed in vivo by intravenous injection, which may be ascribed to its inferior physicochemical properties including water insolubility, short plasma half-time, and insufficient enrichment in the tumor tissues.

methodsThe DSPE-PEG was used to construct quercetin-loaded micelles, and the integrin ligand cRGDfK was grafted to modify the nanocarrier for enhancing its cancer-specific homing. The MALDI-TOF-MS, DLS, TEM, and UV were orderly operated to characterize guidance molecules and micelles by morphology, size distribution, Zeta potential, and drug encapsulation efficiency. In addition, the surface plasmon resonance study and real-time confocal analysis were employed to demonstrate α

resultsThe cRGDfK was successfully stitched with DSPE-PEG and modified on the surface of micelles. The ligand modification enhanced the negative charges of the micelles, but it did not induce significant changes in particle size. The quercetin micelles were about 15 nm in size and negatively charged, and had spherical morphology and high drug encapsulation efficiency. In vitro, the cRGDfK-modified micelles (cRGDfK-PM) showed α

conclusionQuercetin as a natural product has triggered increasing interest in the antitumor field. In this study, cRGDfK-modified DSPE-PEG micelles significantly optimized quercetin therapeutic efficacy and pulmonary toxicity as well as lowered systemic toxicity.

Indexed as

MicellesParticle SizeAnimalsAntineoplastic AgentsApoptosisCell Line, TumorDrugs, Chinese HerbalHumansIntegrin alphaVbeta3MaleMelanoma, ExperimentalMice, NudePeptides, CyclicPhosphatidylethanolaminesPolyethylene GlycolsQuercetinAntineoplastic Agentscyclic (arginyl-glycyl-aspartyl-phenylalanyl-lysyl)Drugs, Chinese HerbalIntegrin alphaVbeta3MicellesPeptides, CyclicPhosphatidylethanolaminespolyethylene glycol-distearoylphosphatidylethanolaminePolyethylene GlycolsQuercetincRGDfKintegrinmicellesquercetin

Identifiers

PMID31819425
PMCPMC6886538
OpenAlexW2990456931

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.